Teva Pharmaceutical Industries Limited (ADR)
General ticker "TEVA" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $29.3B (TTM average)
Teva Pharmaceutical Industries Limited (ADR) follows the US Stock Market performance with the rate: 52.5%.
Estimated limits based on current volatility of 1.9%: low 31.16$, high 32.34$
Factors to consider:
- Earnings expected soon, date: 2026-07-29 bmo
- Total employees count: 33950 (-7.8%) as of 2025
- US accounted for 38.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Generic medicine reliance, Market competition, Regulatory and compliance, Supply chain disruptions, Liquidity and credit risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [22.38$, 35.50$]
- 2026-12-31 to 2027-12-31 estimated range: [20.77$, 33.78$]
Financial Metrics affecting the TEVA estimates:
- Positive: with PPE of 10.7 at the end of fiscal year the price was low
- Positive: 7.57 < Operating profit margin, % of 12.51
- Positive: 19.19 < Shareholder equity ratio, % of 19.41 <= 42.57
- Positive: Investing cash flow per share per price, % of 2.06 > -0.60
- Positive: Inventory ratio change, % of 0.20 <= 0.80
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 3.33
- Negative: negative Industry operating income (median)
Short-term TEVA quotes
Long-term TEVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $15,895.00MM | $16,558.00MM | $17,240.00MM |
| Operating Expenses | $15,462.00MM | $16,861.00MM | $15,083.00MM |
| Operating Income | $433.00MM | $-303.00MM | $2,157.00MM |
| Non-Operating Income | $-1,057.00MM | $-981.00MM | $-934.00MM |
| R&D Expense | $953.00MM | $998.00MM | $1,013.00MM |
| Income(Loss) | $-624.00MM | $-1,284.00MM | $1,223.00MM |
| Taxes | $-7.00MM | $676.00MM | $-180.00MM |
| Other Income(Loss) | $2.00MM | $1.00MM | $15.00MM |
| Net Income(Loss)* | $-559.00MM | $-1,639.00MM | $1,410.00MM |
| Stockholders Equity | $7,506.00MM | $5,373.00MM | $7,910.00MM |
| Inventory | $4,021.00MM | $3,007.00MM | $3,178.95MM |
| Assets | $43,479.00MM | $39,326.00MM | $40,748.00MM |
| Operating Cash Flow | $1,368.00MM | $1,247.00MM | $1,649.00MM |
| Capital expenditure | $526.00MM | $498.00MM | $501.00MM |
| Investing Cash Flow | $968.00MM | $792.00MM | $737.00MM |
| Financing Cash Flow | $-1,913.00MM | $-1,791.00MM | $-2,151.00MM |
| Earnings Per Share** | $-0.50 | $-1.45 | $1.23 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.